Serina Therapeutics’ (SER) “Buy” Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Serina Therapeutics (NYSEAMERICAN:SER) in a research report released on Thursday,Benzinga reports. The firm currently has a $8.00 target price on the stock.

Serina Therapeutics Trading Down 11.2%

Serina Therapeutics stock opened at $2.22 on Thursday. Serina Therapeutics has a one year low of $1.22 and a one year high of $5.83. The company’s fifty day moving average price is $2.38 and its two-hundred day moving average price is $2.06. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.65 and a quick ratio of 6.65. The company has a market capitalization of $56.39 million, a price-to-earnings ratio of -1.17 and a beta of 1.18.

Serina Therapeutics (NYSEAMERICAN:SER) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.55) earnings per share for the quarter.

About Serina Therapeutics

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.